Algernon Pharmaceuticals Inc AGNPF

Primary Symbol: C.AGN

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by waves1on Jul 26, 2022 3:53pm

72 Views

Post# 34851995

IPF's orphan disease indication beneficial to AGN

More on Algernon's ($AGN.c $AGNPF) Phase 2a study of Ifenprodil:
https://themarketherald.ca/crossing-the-finish-line-algernon-cseagn-reaches-endpoint-in-phase-2a-study-of-ifenprodil-2022-07-22/

As IPF seriously compromises the quality of life of those with it, with no full cure and the lack of effective treatment, AGN would be entering a market with essentially no competition, plus, any approved drugs are provided a 7-10 year market exclusivity as IPF has been classified as an "orphan disease indication"

<< Previous

Bullboard Posts

Next >>

Canada Goose appoints first creative director